Candel Therapeutics (CADL) Capital Expenditures (2020 - 2025)
Candel Therapeutics recorded quarterly Capital Expenditures of -$46000.0 in Q4 2025, down 127.88% quarter-over-quarter from $165000.0 in Q3 2025, and down 453.85% year-over-year from $13000.0 in Q4 2024.
Candel Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at -$46000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures fell 453.85% year-over-year to -$46000.0; the TTM figure through Dec 2025 stood at $132000.0 (up 725.0% YoY), while the FY2025 annual figure was $132000.0, up 725.0% from the prior year.
- Capital Expenditures came in at -$46000.0 for Q4 2025 at Candel Therapeutics, down from $165000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.8 million in Q1 2021 to a low of -$911000.0 in Q2 2021.
- A 5-year average of $125450.0 and a median of $31500.0 in 2023 frame the typical range for Capital Expenditures.
- On a YoY basis, Capital Expenditures climbed as much as 1750.0% in 2025 and fell as far as 453.85% in 2025.
- Candel Therapeutics' Capital Expenditures stood at $504000.0 in 2021, then sank by 138.1% to -$192000.0 in 2022, then surged by 124.48% to $47000.0 in 2023, then plunged by 72.34% to $13000.0 in 2024, then slumped by 453.85% to -$46000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$46000.0, $165000.0, and -$3000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -46,000.00 |
| Dec 31, 2025 | -46,000.00 |
| Sep 30, 2025 | 165,000.00 |
| Sep 30, 2025 | 165,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Sep 30, 2023 | 103,000.00 |
| Sep 30, 2023 | 103,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Mar 31, 2023 | 66,000.00 |
| Mar 31, 2023 | 66,000.00 |
| Dec 31, 2022 | -192,000.00 |
| Dec 31, 2022 | -192,000.00 |
| Sep 30, 2022 | -545,000.00 |
| Sep 30, 2022 | -545,000.00 |
| Jun 30, 2022 | 385,000.00 |
| Jun 30, 2022 | 385,000.00 |
| Mar 31, 2022 | 421,000.00 |
| Mar 31, 2022 | 421,000.00 |
| Dec 31, 2021 | 504,000.00 |
| Dec 31, 2021 | 504,000.00 |
| Sep 30, 2021 | 392,000.00 |
| Sep 30, 2021 | 392,000.00 |
| Jun 30, 2021 | -911,000.00 |
| Jun 30, 2021 | -911,000.00 |
| Mar 31, 2021 | 1.85 Mn |
| Mar 31, 2021 | 1.85 Mn |
| Dec 31, 2020 | 1.41 Mn |
| Dec 31, 2020 | 1.41 Mn |
| Sep 30, 2020 | -228,000.00 |
| Sep 30, 2020 | -228,000.00 |